-
Study aim
-
Comparison of therapeutic effect of different concentrations of Triamcinolone Acetoneide injection in Alopecia Areata
-
Design
-
A randomized controlled trial, parallel group, single-blind and is divided into three groups of 15 with coin hair loss in head.
-
Settings and conduct
-
Background: High prevalence of disease and its importance in causing various psychological problems and decreasing self-esteem and social function of patients,
Study Area: Patients Referred to Dermatology Clinic of Sina Hospital in Tabriz,
Procedure and Method of Blindness: In all specimens with more than one lesion, if there is a lesion more than 3 cm away from central lesion at site of drug injection, blind as placebo. will be. Sample size is randomly divided into three groups of 15 people. After informed consent from the patients, the drug is injected.
-
Participants/Inclusion and exclusion criteria
-
Inclusion Criteria: Alopecia areata patients with one or more patch lesions,
Patients 15 years and older,
Patients with full consent to participate in the study,
Disease for 3 to 12 months without any signs of new hair growth at the lesion site,
Exclusion Criteria:Children,
Background or presence of skin diseases such as psoriasis, seborrheic dermatitis, and malignancy and infection at the site
Patients with malignancy and blood dyscrasia,
Pregnant and lactating women,
Patients with mental retardation and physical disability,
Patients who have received topical or systemic corticosteroids and topical treatments in Alopecia Areata or immunosuppressive drugs over the past month,
People with autoimmune thyroid disease, type I diabetes, vitiligo, etc,
A history of epilepsy (seizure).
-
Intervention groups
-
Different concentrations of Triamcenolone Acetoneide will be injected intralesional in doses of 2.5 mg per ml, 5 mg per ml and 10 mg per ml.
-
Main outcome variables
-
New Hear Growth, Number & Length of Them.